

VPA22020/017/001

**Fortekor 2.5 mg tablets for cats and dogs**

<b>Variation</b>	<b>Summary</b>	<b>Date</b>
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	09/10/24
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	09/10/24
Vet - C10 b)	VNRA - Vet - C10 b) - b) Other changes - C10 b) Changes to the safety, efficacy and pharmacovigilance part of the dossier: Changes to the labelling or the package leaflet which shall not be connected with the SPC: — other changes	16/05/24
Vet - G.I.19	VRA-R - Vet - G.I.19 - G.I.19 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet to implement the outcome of the MAH's signal management process according to Article 81(2) of Regulation (EU) 2019/6 - G.I.19 - SAFETY, EFFICACY, PHARMACOVIGILANCE CHANGES - Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet to implement the outcome of the MAH's signal management process according to Article 81(2) of Regulation (EU) 2019/6	15/05/24
Vet - B43	VNRA - Vet - B43 - Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible - B43 Changes to the quality part of the dossier: Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible	05/03/24
Vet - B12 a)	VNRA - Vet - B12 a) - a) Minor changes to an approved test procedure (active, finished product, packaging, measuring device) - B12 a) Changes to the quality part of the dossier: Minor changes — to an approved test procedure — for active substance; — for the finished product; —for the immediate packaging of the active substance or the finished product; — of a measuring or administration device	05/03/24
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 -	25/05/23

	G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	
B.II.b.3.z	IB - B.II.b.3.z - z Other variation - B.II.b.3.z - QUALITY CHANGES - FINISHED PRODUCT - Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - Other variation	01/02/22
B.II.b.3.z	IB - B.II.b.3.z - z Other variation - B.II.b.3.z - QUALITY CHANGES - FINISHED PRODUCT - Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - Other variation	01/02/22
A.7	IA - A.7 - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - A.7 - ADMINISTRATIVE CHANGES - Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)*	28/01/22